130results about How to "Prevention and treatment" patented technology

Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. A method for making the microparticles is provided as well as methods for using the microparticles for controlled digestion of starch on ingestion in the small intestine and methods for using the microparticles to deliver dietary fiber. The microparticles with entrapped starch provide a low glycemic index and extended glucose release in food products and food ingredients. The microparticles with entrapped starch can, in particular, be used as an ingredient in foods that are to be cooked.

The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

It is intended to provide preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.

The present invention is directed to compositions that are useful in the prevention and treatment of common cold and influenza-like symptoms due to respiratory tract viral infections. These compositions comprise a guaiacol component, and a mucoadhesive polymer wherein the pH of the composition is about 5.5 or less.

This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.

A microorganism which belongs to the genus Gliocladium and has the ability to produce stereoisomers KF-1040T4A and KF-1040T4B which are compounds represented by the following formula [I],and stereoisomers KF-1040T5A and KF-1040T5B which are compounds represented by the following formula [II],is cultivated in a culture medium to accumulate KF-1040T4A and / or KF-1040T4B and / or KF-1040T5A and / or KF-1040T5B in the culture medium, and the substance KF-1040T4A and / or KF-1040T4B and / or KF-1040T5A and / or KF-1040T5B are harvested from the culture medium. The obtained substances are useful for the prevention and treatment of the diseases relating to arteriosclerosis, obesity, thrombosis, inflammations and immunofunctional disorders.

The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum. Further, the present invention relates to a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella Enteritidis or Salmonella Typhimurium, Fowl Typhoid caused by Salmonella Gallinarum, and Pullorum disease caused by Salmonella Pullorum, comprising the bacteriophage as an active ingredient. Furthermore, the present invention relates to a feed additive, drinking water, a cleaner and a sanitizer, comprising the bacteriophage as an active ingredient.

Non-steroidal anti-infammatory after shave preparations to aid in the prevention and treatment of Pseudofolliculitis Barbae and a method of delivering the ingredients of the preparation to affected areas of the skin. Formula I comprises ethanol, salicylic acid, propylene glycol, glycerine, fragrance, at least one compound for reducing skin irritation and at least one non-steroidal anti-inflammatory agent wherein said non-steroidal anti-inflammatory agent is an NSAID drug, a naturally occurring herbal compound containing an anti-inflammatory component or combinations thereof. Formula 11 comprises water, hydrolyzed oat flour, sorbitol, methylparaben, petrolatum, lanolin, cetyl alcohol, sunflower seed oil, stearic acid, propylparaben, triethanoloamine, a preservative, and at least one non-steroidal anti-inflammatory agent wherein said non-steroidal anti-inflammatory agent is an NSAID drug, a naturally occurring herbal compound containing an anti-inflammatory component or combinations thereof. The formulas have sufficient viscosity to allow the after shave preparation to remain on an affected area of the skin for a sufficient period of time to optimize the skin irritation reduction and anti inflammatory effects on the affected area thus providing local relief from irritation due to PFB.

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.

The present invention relates to the treatment of gastrointestinal disease and / or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and / or prevention of gastrointestinal disease and / or infection and / or diarrhea and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition or feed additive, comprising an effective amount of a polymer and / or copolymer, having the repeating polymeric unit (I) wherein R is H or alkyl, usually C1 to C4, or this unit in hydrated, hemiacetal or acetal form, together with a pharmaceutically or veterinarally acceptable carrier, diluent, adjuvant, excipient and / or controlled release system.

An object is to provide a method for determining the risk of arteriosclerotic disease which can accurately determine the tendency to develop an arteriosclerotic disease or tendency for advance thereof as the risk of arteriosclerotic disease and can be utilized in prevention and treatment of arteriosclerosis and to provide, for example, a kit for analyzing genetic polymorphism and apparatus for determining the risk of arteriosclerotic disease for use in determination of the risk. A method for determining the risk of arteriosclerotic disease includes a risk evaluation process for evaluating the risk of arteriosclerosis caused by genetic polymorphisms, based on the risk of arteriosclerosis inherent to a combination of plural genetic polymorphisms, from the genotype of a subject on the genetic polymorphisms, in which the combination of plural genetic polymorphisms includes at least one combination of genetic polymorphisms having a significant positive correlation with the carotid arterial intima-media thickness.

Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and / or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention.

The present invention is directed to a food composition including an edible base mix component and a dried probiotic component which that may be stored at room temperature and converted to a frozen dessert with minimal effects to the viability of probiotics. Accordingly, a consumer ingesting the frozen dessert is provided with a beneficial amount of viable probiotics. Also provided herein are one or more methods for manufacturing the food compositions and using the subject food composition in frozen dessert products.

The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.

The invention relates to the field of traditional Chinese medicines, especially relates to a traditional Chinese medicine composition, and application and preparation method thereof, cold tea and a preparation method thereof, a medicinal preparation and a cosmetic. The traditional Chinese medicine composition is prepared from, in parts by weight, 9-18 parts of flos lonicerae, 2-8 parts of flos chrysanthemi, 1-5 parts of radix glycyrrhizae, 1-5 parts of herba lophatheri, 1-5 parts of herba menthae, 1-5 parts of spica prunellae, 1-5 parts of fructus lycii, 1-5 parts of fructus momordicae, and other raw materials. The traditional Chinese medicine composition possesses the efficacy of enhancing immunity and treating wind-heat cold, also possesses effects of resisting oxidation and maintaining beauty, has certain auxiliary treatment effect on diabetes, melancholia, hypertension, bronchitis and the like, also is capable of effectively treating excessive internal heat, heatstroke and constipation, contains heat, protein, carbohydrates, sodium and multiple elements, and other nutrients beneficial to human body, has the color, taste and other physical and chemical and hygienic indexes according to national standard requirements, and is extremely light in original unpleasant taste, sweet in taste and good in mouthfeel.

The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I):wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, -(CH2)q-, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of(wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.

[Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc.[Solving Means] A phenylimidazole compound represented by the following General Formula (1):wherein, R1 represents a hydrogen atom, a phenyl lower alkyl group optionally having a substituent, or a pyridyl lower alkyl group optionally having a substituent, and the benzene ring and the pyridine ring are optionally substituted with 1 or 2 substituents selected from the group consisting of halogen atoms, cyano group and halogen-substituted lower alkyl groups. One of R2 and R3 represents a hydrogen atom and the other represents a lower alkoxy group. R4 represents a phenyl group optionally having a substituent. R5 and R6 are the same or different, and represent a hydrogen atom or a lower alkyl group. R7 and R8 are the same or different, and represent a hydrogen atom or a lower alkoxy group. However, when R1 represents an unsubstituted phenyl lower alkyl group, R2 represents a lower alkoxy group, R3 represents a hydrogen atom, R4 represents a phenyl group optionally having a substituent, and R5 represents a hydrogen atom, R6 is not a hydrogen atom.

The invention discloses a preparation method of a live vector vaccine for controlling chicken coccidiosis, comprising the following steps of obtaining a recombinant expression vector by connecting a mature peptide of an eimeria tenella sporozoite antigen gene 3-1E gene and an expression vector of bacillus subtilis, obtaining a recombinant strain by transferring the recombinant expression vector into a bacillus subtilis host, and culturing the recombinant strain to finally obtain the live vector vaccine for controlling the chicken coccidiosis by. The live vector vaccine can be used for controlling and / or treating the chicken coccidiosis. The invention also discloses an oral biological preparation for controlling the chicken coccidiosis, prepared by utilizing the live vector vaccine. The oral biological preparation comprises the live vector vaccine and a vector. The oral biological preparation per gram contains the live vector vaccine with a living bacteria number of 108-109cfu.

The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.

The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.

This disclosure relates to a composition for prevention or treatment of neurodegenerative disease comprising longan arillus extract, or combined extract comprising longan arillus. The composition exhibits remarkably excellent prevention or treatment effect of neurodegenerative disease by containing longan arillus extract or combined extract comprising longan arillus, and particularly, it may effectively prevent or treat neurodegenerative disease by significantly protecting dopaminergic neurons from neurotoxicity due to MPTP selectively acting on dopaminergic nervous system and neurotoxicity due to aggregation of alpha-synuclein proteins.

This invention relates to a method of inhibiting OPN production, which comprises administering an effective amount of a pyridazine derivative represented by the following formula (I) or a salt thereof: wherein: R1 means a substituted or unsubstituted phenyl or pyridyl group; R2 means a substituted phenyl group; R3 means a hydrogen atom or a substituted or unsubstituted phenyl or pyridyl group; A means a single bond, a C1-6 linear or branched alkylene group, or a C2-9 linear or branched alkenylene group; and X means an oxygen atom or a sulfur atom.

The present invention relates to use of ginsenoside Rg3, Rg5 or Rk1, or extract of ginseng, red ginseng or processed ginseng comprising the ginsenosides; a composition for preventing or treating angiostenosis and restenosis comprising the ginsenosides or extracts; a method for preventing or treating angiostenosis and restenosis by administrating the ginsenosides or extracts comprising the ginsenosides; and a preparation method of agents for preventing or treating angiostenosis and restenosis. The present composition can effectively prevent or treat angiostenosis and restenosis.

The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma.

The invention relates to a protein material includes angiogenin and / or angiogenin hydrolysate in an amount of 2 to 15 mg / 100 mg, and lactoperoxidase and / or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and / or angiogenin hydrolysate of 0.3 to 20.

The present invention relates to a liquid pharmaceutical composition containing an N-phenylpyrazole derivative as active ingredient and alpha-(tetrahydrofuranyl)-omega-hydroxypoly(oxy-1,2-ethanediyl) as solvent for the treatment and / or prevention of infestations with fleas in domestic animals.